Breaking Finance News

Impax Laboratories Inc (NASDAQ:IPXL) has been downgraded to Sell in a report by Zacks Investment Research today.

Zacks Investment Research has downgraded Impax Laboratories Inc (NASDAQ:IPXL) to Sell in a report released on 10/17/2016.

On 9/27/2016, Goldman Sachs Group Inc. released a statement about Impax Laboratories Inc (NASDAQ:IPXL) upped the target price from $25.00 to $26.00 that suggested an upside of 0.02%.

Having a price of $21.80, Impax Laboratories Inc (NASDAQ:IPXL) traded 0.23% higher on the day. With the last stock price down -25.86% from the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the same period. IPXL has recorded a 50-day average of $24.50 and a two hundred day average of $29.34. Trade Volume was down over the average, with 785,822 shares of IPXL changing hands under the typical 974,872

Recent Performance Chart

Impax Laboratories Inc (NASDAQ:IPXL)

Impax Laboratories Inc has PE ratio of 46.08 with a one year low of $20.97 and a one year high of $45.00 and has a market capitalization of $0.

A total of 14 brokerages have issued a ratings update on Impax Laboratories Inc. Two brokerages rating the company a strong buy, three brokerages rating the company a buy, seven brokerages rating the company a hold, three equity analysts rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $35.79.

Brief Synopsis About Impax Laboratories Inc (NASDAQ:IPXL)

Impax Laboratories, Inc. is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), as well as the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma. The Impax Generics segment is focused on the development, manufacture, sale and distribution of its generic products, which are the pharmaceutical and therapeutic equivalents of brand-name drug products and are marketed under their established drug names. The Impax Specialty Pharma segment is engaged in the promotion, sale and distribution of various branded products, including its branded pharmaceutical product, Rytary, an extended release oral capsule formulation of carbidopa-levodopa for the treatment of Parkinson's disease, post-encephalitic Parkinsonism and Parkinsonism, and Zomig (zolmitriptan) products, indicated for the treatment of migraine headaches.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.